OncoMatch/Clinical Trials/NCT07066995
Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer
Is NCT07066995 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Mesothelin and Claudin 18.2 CAR-T cells for pancreatic cancer.
Treatment: Mesothelin and Claudin 18.2 CAR-T cells — Autologous T-cells engineered to express CARs targeting Mesothelin and Claudin18.2, for Unresectable locally advanced or metastatic pancreatic adenocarcinoma (Pancreatic Ductal Adenocarcinoma, PDAC), administered as two separate sequential infusions following lymphodepleting chemotherapy
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: systemic therapy (gemcitabine, nab-paclitaxel, FOLFIRINOX) — advanced disease
Patients should have received, or be intolerant of, standard first-line therapy (e.g., gemcitabine/nab-paclitaxel, FOLFIRINOX) for advanced disease. ... evidence of disease progression on or after at least one line is required prior to infusion
Cannot have received: CAR-T therapy
Patients who received CAR-T therapy or other gene-modified cell therapy before screening
Cannot have received: gene-modified cell therapy
Patients who received CAR-T therapy or other gene-modified cell therapy before screening
Lab requirements
Kidney function
creatinine ≤1.5×uln
Liver function
total bilirubin ≤2×uln; alt and ast≤2.5 x uln; alt and ast abnormalities due to disease, such as liver infiltration or bile duct obstruction, were determined to be less than 5×uln. if gilbert syndrome is diagnosed, the total bilirubin index can be relaxed to ≤3.0×uln and the direct bilirubin ≤1.5×uln.
Cardiac function
electrocardiogram showed no clinically significant abnormal bands; blood oxygen saturation >91% in non-oxygen state
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07066995 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CAR-T therapy, gene-modified cell therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 90 years or younger and at least 21 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages